Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?

被引：3
|
作者：
Vijayshree Yadav
Dennis Bourdette
机构：
[1] Oregon Health & Science University,Department of Neurology
来源：
Current Neurology and Neuroscience Reports | 2010年 / 10卷 / 5期
关键词：
Multiple Sclerosis; Natalizumab; Glatiramer Acetate; Fingolimod; Cladribine;
D O I：
10.1007/s11910-010-0126-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：333 / 335
页数：2
相关论文
共 50 条
  • [41] Use of the New Oral Disease-Modifying Therapies for Multiple Sclerosis: The First Five Years
    Setayeshgar, Solmaz
    Kingwell, Elaine
    Zhu, Feng
    Zhang, Xinyu
    Zhang, Tingting
    Marrie, Ruth Ann
    Carruthers, Robert
    Tremlett, Helen
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 52 - 52
  • [42] Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
    Eagle, Tessa
    Stuart, Fiona
    Chua, Alicia S.
    LaRussa, Allison
    Leclaire, Kaitlynne
    Cook, Sandra L.
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie I.
    Healy, Brian C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 196 - 201
  • [43] Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies
    McGinley, Marisa P.
    Cola, Philip A.
    Fox, Robert J.
    Cohen, Jeffrey A.
    Corboy, John J.
    Miller, Deborah
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (12) : 1581 - 1589
  • [44] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
  • [45] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Grebenciucova, Elena
    Pruitt, Amy
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (11)
  • [46] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [47] Disease-modifying therapies in multiple sclerosis: A focused review of rituximab
    Alping, Peter
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2023, 133 (05) : 550 - 564
  • [48] Reason for hope: The advent of disease-modifying therapies in multiple sclerosis
    O'Connor, PW
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2000, 162 (01) : 83 - 84
  • [49] The emergence of follow-on disease-modifying therapies for multiple sclerosis
    Moss, Brandon P.
    Cohen, Jeffrey A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (12) : 1560 - 1565
  • [50] Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
    Ali Manouchehrinia
    Cris S. Constantinescu
    [J]. Current Neurology and Neuroscience Reports, 2012, 12 : 592 - 600
12345